Home
Forms Library
Proposed Proprietary - accessdata fda

Proposed Proprietary - accessdata fda 2025

Proposed Proprietary - accessdata fda Preview on Page 1

Show details

4.7 out of 5

55 votes

The document is a microbiology review for the New Drug Application (NDA) 22-439/N000 submitted by Cypress Pharmaceuticals for a non-sterile oral pharmaceutical product containing Hydrocodone Bitartrate, Pseudoephedrine Hydrochloride, and Chlorpheniramine Maleate. The review concludes with a recommendation to approve the application from a quality microbiology standpoint, noting no deficiencies in microbiology assessments.

Here's how it works

01. Edit your form online

Type text, add images, blackout confidential details, add comments, highlights and more.

02. Sign it in a few clicks

Draw your signature, type it, upload its image, or use your mobile device as a signature pad.

03. Share your form with others

Send it via email, link, or fax. You can also download it, export it or print it out.

The best way to modify Proposed Proprietary - accessdata fda in PDF format online

Ease of Setup

DocHub User Ratings on G2

Ease of Use

DocHub User Ratings on G2

Adjusting documents with our extensive and intuitive PDF editor is straightforward. Follow the instructions below to complete Proposed Proprietary - accessdata fda online quickly and easily:

Log in to your account. Log in with your email and password or register a free account to try the service prior to upgrading the subscription.
Import a form. Drag and drop the file from your device or import it from other services, like Google Drive, OneDrive, Dropbox, or an external link.
Edit Proposed Proprietary - accessdata fda. Easily add and highlight text, insert pictures, checkmarks, and signs, drop new fillable areas, and rearrange or remove pages from your document.
Get the Proposed Proprietary - accessdata fda completed. Download your updated document, export it to the cloud, print it from the editor, or share it with other participants via a Shareable link or as an email attachment.

Make the most of DocHub, one of the most easy-to-use editors to promptly handle your documentation online!

be ready to get more

Complete this form in 5 minutes or less

Get form

Got questions?

We have answers to the most popular questions from our customers. If you can't find an answer to your question, please contact us.

What is the FDA approval of 505b2?

The provisions of 505(b)(2) were created, in part, to help avoid unnecessary duplication of studies already performed on a previously approved (reference or listed) drug; the section gives the FDA express permission to rely on data not developed by the NDA applicant.

What is the success rate of 505b2?

While exact success rates can vary based on the specific drug and modifications being proposed, industry analyses suggest that 505(b)(2) applications have a higher likelihood of approval, often cited to be around 70-75%, compared to the significantly lower success rates typically associated with new molecular entity (

What is an example of a proprietary name?

Example Sentences A ruby is often not labeled as such, but it may be called reserve or have a proprietary name, such as Grahams Six Grapes. Its generic name, olaparib, has now been awarded the proprietary name of Lynparza.

What is 505 B1?

The 505(b)(1) is a USFDA (United States Food and Drug Administration) Regulatory pathway traditionally known as New Drug Application (NDA). The Regulatory pathway is used to obtain approval for new drugs with previously unapproved active ingredients.

What is the difference between 505b and 505b2?

505(b)(2) programs by definition require fewer and/or smaller studies than 505(b)(1) products require, and the costs are significantly less in every phase of development. Additionally, it is more likely that nonclinical and clinical commitments for a 505(b)(2) product can be met post-market.

What is the continued access protocol FDA?

Continued Access (Extended Investigation) of an Unapproved Medical Device. FDA may allow continued enrollment of subjects after the clinical trial under an IDE has been completed to allow access to the investigational medical device while the marketing application is being prepared by the sponsor or reviewed by FDA.

What is the exclusivity of FDA 505 B )( 2?

Exclusivity potential: Products approved under 505(b)(2) may qualify for various types of market exclusivity: Orphan drug exclusivity (7 years) New chemical entity exclusivity (5 years) Other exclusivity (3 years for a change if certain criteria are met)

Does Pdufa mean FDA approval?

Background and Legislation. The Prescription Drug User Fee Act (PDUFA) was created by Congress in 1992 and authorizes FDA to collect user fees from persons that submit certain human drug applications for review or that are named in approved applications as the sponsor of certain prescription drug products.

Proposed Proprietary - accessdata fda 2025

Here's how it works